Kopran Stock Falls to 52-Week Low of Rs.131 Amidst Continued Downtrend

On 19 Nov 2025, Kopran's stock price touched Rs.131, its lowest level in the past year. Despite opening the day with a gap up of 4.57%, reaching an intraday high of Rs.141.85, the stock ultimately declined to its intraday low of Rs.131, closing with a day change of -1.92%. This performance underperformed its sector by 1.18%, indicating relative weakness within the Pharmaceuticals & Biotechnology industry.

The stock has been on a consecutive seven-day losing streak, resulting in a cumulative return decline of 17.09% during this period. Kopran is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a persistent bearish trend in the short to long term.

In comparison, the broader market has shown resilience. The Sensex opened flat with a minor decline of 29.24 points and is trading at 84,657.26, just 0.75% below its 52-week high of 85,290.06. The Sensex is supported by bullish moving averages, with the 50-day moving average positioned above the 200-day moving average. Mid-cap stocks have also shown slight gains, with the BSE Mid Cap index up by 0.02% today.

Over the last year, Kopran's stock has generated a return of -35.82%, significantly underperforming the Sensex, which recorded a positive return of 9.12% over the same period. The stock's 52-week high was Rs.236.10, highlighting the extent of the decline to the current low.

Financially, Kopran has faced challenges reflected in its recent quarterly results. The company reported a net sales decline of 22.2% in the September 2025 quarter, contributing to a series of five consecutive quarters with negative results. The quarterly profit after tax (PAT) stood at Rs. -9.92 crore, representing a fall of 234.4% compared to previous periods.

Return on capital employed (ROCE) for the half-year period is at a low 5.38%, while the operating profit to interest ratio for the quarter is at -2.53 times, indicating that operating profits are insufficient to cover interest expenses. These metrics point to subdued profitability and financial strain within the company.

Despite these challenges, Kopran maintains a relatively low average debt-to-equity ratio of 0.23 times, suggesting limited leverage compared to many peers in the Pharmaceuticals & Biotechnology sector. The enterprise value to capital employed ratio stands at 1.3, which is considered attractive relative to historical valuations of comparable companies.

Domestic mutual funds hold a minimal stake in Kopran, accounting for only 0.01% of the company’s shares. Given their capacity for detailed research, this small holding may reflect a cautious stance towards the stock’s current valuation and business performance.

Examining Kopran’s long-term performance, the company’s operating profit has declined at an annual rate of 11.79% over the past five years. The stock has also underperformed the BSE500 index over the last three years, one year, and three months, indicating persistent challenges in generating shareholder returns.

Volatility has been a notable feature of Kopran’s trading activity. On the day it hit the 52-week low, the stock exhibited an intraday volatility of 5.07%, calculated from the weighted average price. This heightened price fluctuation reflects uncertainty and active repositioning by market participants.

In summary, Kopran’s fall to Rs.131 marks a significant low point in its recent trading history, underscored by weak financial results, subdued profitability metrics, and sustained downward price momentum. While the broader market and sector indices have shown relative strength, Kopran’s performance remains subdued, with key indicators signalling ongoing challenges.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →